- Home
- KMI vs INM Comparison
KMI vs INM Comparison
Compare KMI & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMI
- INM
- Stock Information
- Founded
- KMI 1936
- INM 1981
- Country
- KMI United States
- INM Canada
- Employees
- KMI N/A
- INM N/A
- Industry
- KMI Natural Gas Distribution
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- KMI Utilities
- INM Health Care
- Exchange
- KMI Nasdaq
- INM Nasdaq
- Market Cap
- KMI 62.2B
- INM 3.2M
- IPO Year
- KMI 2011
- INM N/A
- Fundamental
- Price
- KMI $28.36
- INM $2.73
- Analyst Decision
- KMI Buy
- INM
- Analyst Count
- KMI 16
- INM 0
- Target Price
- KMI $28.25
- INM N/A
- AVG Volume (30 Days)
- KMI 13.0M
- INM 5.7M
- Earning Date
- KMI 07-21-2025
- INM 05-12-2025
- Dividend Yield
- KMI 4.13%
- INM N/A
- EPS Growth
- KMI 5.43
- INM N/A
- EPS
- KMI 1.16
- INM N/A
- Revenue
- KMI $15,499,000,000.00
- INM $4,920,990.00
- Revenue This Year
- KMI $9.70
- INM N/A
- Revenue Next Year
- KMI $4.74
- INM N/A
- P/E Ratio
- KMI $24.49
- INM N/A
- Revenue Growth
- KMI 1.38
- INM N/A
- 52 Week Low
- KMI $19.68
- INM $1.72
- 52 Week High
- KMI $31.48
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- KMI 52.70
- INM 45.84
- Support Level
- KMI $27.88
- INM $3.32
- Resistance Level
- KMI $28.57
- INM $5.50
- Average True Range (ATR)
- KMI 0.61
- INM 0.36
- MACD
- KMI 0.00
- INM -0.02
- Stochastic Oscillator
- KMI 46.74
- INM 14.51
About KMI Kinder Morgan Inc.
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 80,000 miles of gas, refined products, and carbon dioxide pipelines. The company also owns one of the largest portfolios of gas and refined products storage and terminals. Most of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.